On September 4, 2019 Jounce Therapeutics, Inc. (the "Company") Presented the corporate presentation (Presentation, Jounce Therapeutics, SEP 4, 2019, View Source [SID1234539295]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 4, 2019, Halozyme Therapeutics, Inc. presented the corporate presentation (Presentation, Halozyme, SEP 4, 2019, View Source [SID1234539294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 4, 2019 RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at The Fall Investor Summit on September 16-17, 2019, in New York City (Press release, RegeneRx Biopharmaceuticals, SEP 4, 2019, View Source [SID1234539293]). The specific presentation date, time and webcast information will be announced as soon as determined by the conference schedulers. The Company will not be presenting at the Rodman & Renshaw Investment Conference on September 8-10 as was previously announced.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 4, 2019 Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI;OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, reported that Jesse Ledger, Nuvo’s President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City (Press release, Nuvo Pharmaceuticals, SEP 4, 2019, https://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-to-present-at-hc-wainwright-global-investment-conference-300911283.html [SID1234539292]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nuvo Presentation Details

Date:

Tuesday, September 10, 2019

Time:

5:00 p.m.

Location:

Lotte New York Palace Hotel

A link to the live audio webcast of the presentation will be available on the Home Page of the Company’s website at www.nuvopharmaceuticals.com. The archived webcast will be available for 30 days.

Mr. Ledger will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the Company should contact conference coordinators to arrange an appointment or contact Nuvo directly via email at [email protected].

On September 4, 2019 Accuray Incorporated (NASDAQ: ARAY) reported that the Company will host an Investor Meeting during the American Society of Radiation Oncology (ASTRO) Annual Meeting, being held in Chicago, IL (Press release, Accuray, SEP 4, 2019, View Source [SID1234539291]). The presentations will commence at 3:00pm CT (4:00pm ET/1:00pm PT) and will conclude at 5:30pm CT (6:30pm ET/3:30pm PT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program will include presentations by Accuray’s senior management team and clinical key opinion leaders about the Company’s solutions for addressing today’s cancer challenges and will also include question and answer sessions. The topics being discussed include: Solutions for Today’s Market, the Radixact System and the advanced Synchrony Motion Tracking and Correction Technology1, the CyberKnife System and CyberKnife VOLO Optimizer Technology, and U.S. Reimbursement Developments.

Due to the limited space, guests must register to attend Accuray’s ASTRO investor meeting. Please RSVP to Michael Polyviou at [email protected] by Monday, September 9, 2019.

For those not attending the ASTRO meeting, a webcast will be available on the Investor Relations page of the Company’s website at View Source A replay of the webcast will also be available on the Company’s website following the event.